Tom Swallow

Vice President, Finance

Tom Swallow joined VentiRx in 2011 as Vice President, Finance bringing more than 25 years experience in finance and accounting. Before joining VentiRx, Mr. Swallow served as Senior Director, Finance for Calistoga Pharmaceuticals, a privately held biotechnology company developing innovative therapeutics for patients with cancer or inflammatory diseases. Calistoga was acquired by Gilead in April 2011. At Calistoga, Mr. Swallow was responsible for managing finance and accounting operations and instituting financial systems.

Prior to Calistoga, Mr. Swallow worked at ICOS, a biotechnology company engaged in the discovery and development of product candidates for the treatment of serious medical diseases, where he held the position of Controller and then Director of Finance. ICOS was acquired by Eli Lily in January 2007. During his more than 16 years at ICOS, Mr. Swallow was involved in oversight of accounting and financing activities and directed a team of financial analysts. Mr. Swallow also worked as Senior Director, Finance for Targeted Genetics and as an Accounting Manager for Maryatt Industries

Mr. Swallow holds a B.S. in Accounting from Central Washington University.